The legacy of Viagra and its effect on the pharmaceutical landscape presents a thorny question for shareholders . Initially a blockbuster drug, generics have significantly chipped away at its market presence , creating challenges for companies involved to the original patent holder and related developments . While certain companies might benefit fr